Live
FierceBiotechAlnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneerEndpoints NewsADC biotech Ona Therapeutics secures $86.6M in Series B raiseBioPharma DiveA Spanish biotech banks $87M to make differentiated ADCsLonza NewsLonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation - Manufacturing ChemistPfizerModerna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge - NAI500IlluminaIs Illumina (ILMN) Quietly Solidifying an End‑to‑End Oncology Moat With Deeper DRAGEN Integration? - simplywall.stMedtronicMedtronic reports strongest annual revenue growth in a decade - Medical Device NetworkClinical OMICsCAR T-Cell Therapy Expands Access to Kidney TransplantsEndpoints NewsAlnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealFierceBiotechLilly, Boehringer to slash at least $1B each from planned investments in GermanyClinical OMICsGenetically Raised Pulse Pressure Predisposes to Dementia-Linked DeathClinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 Diabetes
FierceBiotech Feb 28, 2026

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

Original
Body unavailable. Use the original source.